FDA greenlights blood test for Alzheimer’s disease: How does it work?
The FDA has cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood test for early Alzheimer's detection in adults aged 55 and older showing symptoms. It analyzes pTau217 and beta-amyloid ratios, correlating with brain amyloid plaques. This advancement offers a more accessible and cost-effective alternative to PET scans, potentially enabling earlier intervention and treatment.
Top Stories